title: Hippocampal volume reduction specific for later transition to psychosis or substance-associated effects?
authors.forename: Stefan
authors.initials: S
authors.lastname: Borgwardt
authors.forename: Renata
authors.initials: R
authors.lastname: Smieskova
authors.forename: Kerstin
authors.initials: K
authors.lastname: Bendfeldt
authors.forename: Eva
authors.initials: E
authors.lastname: Bühlmann
authors.forename: Gregor
authors.initials: G
authors.lastname: Berger
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Aston
authors.forename: Ute
authors.initials: U
authors.lastname: Gschwandtner
authors.forename: Marlon
authors.initials: M
authors.lastname: Pflueger
authors.forename: Rolf-Dieter
authors.initials: RD
authors.lastname: Stieglitz
authors.forename: Anita
authors.initials: A
authors.lastname: Riecher-Rössler
authors.forename: Ernst-Wilhelm
authors.initials: EW
authors.lastname: Radue
mesh_terms: D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D042241:Early Diagnosis; D006624:Hippocampus / Q000187:drug effects* / Q000473:pathology*; D006801:Humans; D008279:Magnetic Resonance Imaging; D009929:Organ Size / Q000187:drug effects; D011237:Predictive Value of Tests; D011605:Psychoses, Substance-Induced / Q000175:diagnosis; D011618:Psychotic Disorders / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology / Q000523:psychology; D012307:Risk Factors
chemical_list: D014150:Antipsychotic Agents